Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bullseye: 177Lu-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer
NCT04443062Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2020
- Primary completion
- Apr 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) comparing Interventional arm: 177Lu-PSMA radioligand therapy with Standard of care (2 arms). Primary endpoints: Fraction of patients with disease progression within 6 months and Time to disease progression at 30 weeks. Started Jul 2020; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04443062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443062.